Tirzepatide cuts weight 9.4% and improves behavior in Smith-Magenis syndrome patient
Background
Smith-Magenis syndrome (SMS) is a rare neurodevelopmental disorder marked by intellectual disability, behavioral dysregulation, and severe hyperphagia-driven obesity. Current management often falls short, particularly for the intractable behavioral challenges and metabolic issues. While dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists like tirzepatide have shown efficacy in the general population for weight and metabolic control, their application in SMS, which involves complex central nervous system pathways, has been unexplored.
Study Design
This case report describes a 31-year-old woman diagnosed with Smith-Magenis syndrome (17p11.2 deletion) who presented with lifelong obesity (BMI 32.0-32.9 kg/m2) and aggressive behaviors refractory to standard care. She was initiated on tirzepatide, with the dose gradually titrated to 5 mg weekly. The treatment duration spanned 10 months, during which primary endpoints included weight loss, changes in fasting glucose levels, and caregiver-reported behavioral improvements, specifically focusing on food-seeking behavior, impulsivity, and aggression.
Results
Over 10 months of treatment with tirzepatide, the patient achieved a 9.4% weight loss, equating to 7.3 kg. Concurrently, her fasting glucose levels showed improvement. Caregivers reported notable positive changes in behavior, including a significant reduction in food-seeking behaviors and impulsivity. Quantitative analysis further corroborated a significant reduction in aggression. The treatment was well tolerated throughout the study period, with no adverse events reported. This suggests that targeting both GIP and GLP-1 receptors may influence both metabolic and central nervous system pathways in SMS.
Tirzepatide treatment resulted in a 9.4% weight loss and a significant reduction in aggression in a patient with Smith-Magenis syndrome.
Key Findings
- Tirzepatide achieved 9.4% weight loss (7.3 kg) over 10 months in a patient with SMS.
- Fasting glucose levels improved during the 10-month tirzepatide treatment.
- Caregivers reported reduced food-seeking behavior and impulsivity.
- Quantitative analysis demonstrated a significant reduction in aggression.
- The treatment was well tolerated with no reported adverse events.
Why It Matters
This case report suggests tirzepatide may offer a promising therapeutic strategy for Smith-Magenis syndrome, addressing both the challenging hyperphagia-driven obesity and severe behavioral dysregulation. This dual benefit, targeting metabolic and central nervous system pathways, could significantly improve quality of life for patients and caregivers. The findings also open avenues for exploring GIP/GLP-1 agonism in other neurodevelopmental disorders characterized by syndromic obesity and intractable behavioral issues, such as Prader-Willi syndrome. While a single case, it provides a crucial proof-of-concept for a novel intervention where standard treatments often fail, potentially leading to future cohort studies or clinical trials.
tirzepatide
smith-magenis-syndrome
obesity
hyperphagia
neurodevelopmental-disorder
glp-1-agonist